cilostazol has been researched along with Heart Disease, Ischemic in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of the present study was to investigate whether cilostazol use is associated with a lower risk of incident dementia in Asian patients with IHD, and whether these effects differed based on sex." | 7.88 | Effect of Cilostazol on Incident Dementia in Elderly Men and Women with Ischemic Heart Disease. ( Jung, YS; Kim, MY; Lee, S; Noh, Y; Paik, HY; Shin, S; Son, SJ, 2018) |
| " We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population." | 7.85 | Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study. ( Chang, YH; Chien, CY; Tai, SY; Yang, YH, 2017) |
| "Cilostazol (Pletal), a quinolinone derivative with a cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitory activity, was recently approved by the Food and Drug Administration for treatment of symptoms of intermittent claudication (IC)." | 7.70 | Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. ( Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M, 2000) |
| "The goal of the present study was to investigate whether cilostazol use is associated with a lower risk of incident dementia in Asian patients with IHD, and whether these effects differed based on sex." | 3.88 | Effect of Cilostazol on Incident Dementia in Elderly Men and Women with Ischemic Heart Disease. ( Jung, YS; Kim, MY; Lee, S; Noh, Y; Paik, HY; Shin, S; Son, SJ, 2018) |
| " We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population." | 3.85 | Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study. ( Chang, YH; Chien, CY; Tai, SY; Yang, YH, 2017) |
| "Cilostazol (Pletal), a quinolinone derivative with a cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitory activity, was recently approved by the Food and Drug Administration for treatment of symptoms of intermittent claudication (IC)." | 3.70 | Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. ( Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M, 2000) |
| " This systematic review assesses the efficacy and safety of adjunctive cilostazol to DAT in combination with DAT on reducing clinical adverse events." | 2.49 | Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials. ( Ding, XL; Gao, J; Jiang, B; Miao, LY; Xie, C; Zhang, H; Zhang, JJ; Zhang, LL, 2013) |
| "However, the ratio of stroke to ischemic heart disease is still different between the East and West." | 1.33 | Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy? ( Shinohara, Y, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, MY | 1 |
| Noh, Y | 1 |
| Son, SJ | 1 |
| Shin, S | 1 |
| Paik, HY | 1 |
| Lee, S | 1 |
| Jung, YS | 1 |
| Tai, SY | 1 |
| Chien, CY | 1 |
| Chang, YH | 1 |
| Yang, YH | 1 |
| Lee, SP | 1 |
| Suh, JW | 1 |
| Park, KW | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Chae, IH | 1 |
| Choi, DJ | 1 |
| Rha, SW | 1 |
| Bae, JW | 1 |
| Cho, MC | 1 |
| Kwon, TG | 1 |
| Bae, JH | 1 |
| Kim, HS | 1 |
| Ding, XL | 1 |
| Xie, C | 1 |
| Jiang, B | 1 |
| Gao, J | 1 |
| Zhang, LL | 1 |
| Zhang, H | 1 |
| Zhang, JJ | 1 |
| Miao, LY | 1 |
| Ahn, JC | 1 |
| Song, WH | 1 |
| Kwon, JA | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Rho, YM | 1 |
| Douglas, JS | 1 |
| Holmes, DR | 1 |
| Kereiakes, DJ | 1 |
| Grines, CL | 1 |
| Block, E | 1 |
| Ghazzal, ZM | 1 |
| Morris, DC | 1 |
| Liberman, H | 1 |
| Parker, K | 1 |
| Jurkovitz, C | 1 |
| Murrah, N | 1 |
| Foster, J | 1 |
| Hyde, P | 1 |
| Mancini, GB | 1 |
| Weintraub, WS | 1 |
| Shinohara, Y | 1 |
| Liu, Y | 1 |
| Fong, M | 1 |
| Cone, J | 1 |
| Wang, S | 1 |
| Yoshitake, M | 1 |
| Kambayashi, J | 1 |
| Regensteiner, JG | 1 |
| Hiatt, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for cilostazol and Heart Disease, Ischemic
| Article | Year |
|---|---|
Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Combined Modality Therapy; Cyclooxygenase Inhibitors; | 2013 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
2 trials available for cilostazol and Heart Disease, Ischemic
| Article | Year |
|---|---|
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel | 2010 |
Coronary stent restenosis in patients treated with cilostazol.
Topics: Aged; Angina, Unstable; Aspirin; Cilostazol; Coronary Restenosis; Double-Blind Method; Female; Human | 2005 |
5 other studies available for cilostazol and Heart Disease, Ischemic
| Article | Year |
|---|---|
Effect of Cilostazol on Incident Dementia in Elderly Men and Women with Ischemic Heart Disease.
Topics: Aged; Aged, 80 and over; Cilostazol; Cohort Studies; Dementia; Female; Humans; Male; Myocardial Isch | 2018 |
Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Cilostazol; Cohort Studies; Dementia; Fem | 2017 |
Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel.
Topics: Aspirin; Cilostazol; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femal | 2004 |
Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy?
Topics: Aspirin; Brain Infarction; Cilostazol; Humans; Incidence; Japan; Myocardial Ischemia; Platelet Aggre | 2006 |
Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
Topics: Adenosine; Animals; Blood Pressure; Cilostazol; Dose-Response Relationship, Drug; Heart Rate; Humans | 2000 |